Media coverage about Axsome Therapeutics (NASDAQ:AXSM) has trended somewhat positive on Monday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.8373252390176 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Axsome Therapeutics (NASDAQ:AXSM) remained flat at $5.55 on Monday. 52,502 shares of the company traded hands. The firm’s market capitalization is $131.04 million. The firm has a 50-day moving average of $5.14 and a 200 day moving average of $4.68. Axsome Therapeutics has a 1-year low of $3.53 and a 1-year high of $9.11.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Equities research analysts anticipate that Axsome Therapeutics will post ($1.38) earnings per share for the current fiscal year.

A number of research firms have recently weighed in on AXSM. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $31.00 target price (up previously from $28.00) on shares of Axsome Therapeutics in a report on Wednesday, July 26th. Zacks Investment Research lowered Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, June 16th. Aegis restated a “buy” rating and issued a $20.00 target price on shares of Axsome Therapeutics in a report on Tuesday, June 20th. Finally, ValuEngine upgraded Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.21.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Stock Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related stocks with our FREE daily email newsletter.